Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243738 | 0.77 | SMN1; SMN2 (0.35) | LMNAAPAF1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL678753 | 0.72 | SMN1; SMN2 (0.37) | LMNAAPAF1POLBSMN1; SMN2GLS | |
| SCHEMBL334651 | 0.71 | CYP3A4 (0.33) | LMNAPOLBSMN1; SMN2CPB2ALDH1A1 | |
| SCHEMBL24248353 | 0.71 | PDE2A (0.36) | LMNAAPAF1POLBSMN1; SMN2GLS | |
| SCHEMBL3751699 | 0.70 | LMNA (0.37) | LMNAAPAF1POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL3835193 | 0.70 | SMN1; SMN2 (0.46) | SMN1; SMN2GLSALDH1A1HPGDKDM4E | |
| SCHEMBL23686272 | 0.69 | AAK1 (0.33) | LMNAAPAF1POLBSMN1; SMN2GLS | |
| SCHEMBL23240257 | 0.69 | SMN1; SMN2 (0.39) | LMNAAPAF1POLBSMN1; SMN2GLS | |
| SCHEMBL335380 | 0.68 | MEN1 (0.43) | LMNASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL19102161 | 0.67 | GLS (0.34) | LMNAAPAF1POLBSMN1; SMN2GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | LMNA 1467/4885APAF1 2297/4885POLB 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.